Key Findings
Significant progress is being made in Antibody-Drug Conjugate (ADC)-based combination therapy strategies for Non-Small Cell Lung Cancer (NSCLC). A review published in PubMed highlights the potential of combining ADCs targeting multiple molecular targets, such as Trop-2, HER2, and HER3, with other therapeutic modalities like immune checkpoint inhibitors (ICIs) and EGFR tyrosine kinase inhibitors (TKIs). This multi-targeted approach promises to significantly improve patient outcomes and establish new standards of care for challenging NSCLC populations.
Technical and Clinical Details
ADCs are precision oncology tools that combine the specific targeting capabilities of antibodies with the potent cytotoxic effects of chemotherapy payloads, thereby efficiently destroying cancer cells while minimizing systemic side effects. The advancements in ADC combination therapies for NSCLC are centered around targeting key molecular markers:
- Trop-2: Trop-2 targeting ADCs, such as Datopotamab deruxtecan (Dato-DXd) which has shown success in triple-negative breast cancer, are demonstrating promising results in NSCLC, with ongoing investigations into their combination with ICIs.
- HER2/HER3: Trastuzumab deruxtecan (T-DXd) is already approved for HER2-low NSCLC, and other HER2/HER3-targeting ADCs are in development. These agents may offer new options for patients with EGFR TKI-resistant NSCLC.
- c-Met, B7-H3, CEACAM5, ITGβ6: These emerging targets are also a focus for ADC development. Notably, c-Met is a known resistance mechanism in EGFR-mutated NSCLC after TKI therapy, making c-Met-targeting ADCs a potentially critical therapeutic option.
The review specifically emphasizes combination therapies of ADCs with ICIs. The antigens released upon ADC-mediated cancer cell destruction can activate an immune response, potentially enhancing the efficacy of ICIs. Additionally, in EGFR-mutated NSCLC, combinations of ADCs with TKIs are being explored as a treatment strategy post-TKI resistance, aiming for synergistic effects.
Furthermore, the potential of bispecific ADCs (BsADCs) is discussed. BsADCs, by simultaneously targeting two different antigens, could enhance tumor specificity and achieve more effective drug delivery.
Background and Industry Context
NSCLC accounts for approximately 85% of all lung cancers and is often associated with a poor prognosis. While recent advancements with molecularly targeted drugs for EGFR mutations and ALK fusions, and ICIs like PD-1/PD-L1 inhibitors, have improved outcomes, challenges such as drug resistance and hard-to-treat patient populations persist. ADCs are anticipated to be next-generation therapeutics addressing these unmet medical needs. Combination therapies, in particular, are gaining traction as a strategy to combat the complex biology of cancer and maximize therapeutic effects.
Strategic Significance and Outlook
ADC-based combination therapy strategies for NSCLC are poised for significant evolution in the coming years. The development of ADCs against diverse targets, identification of optimal combination schedules with ICIs and TKIs, and novel designs like bispecific ADCs offer new hope for patients with challenging NSCLC. As personalized medicine advances, optimizing patient selection through biomarkers will become even more critical for the success of these combination therapies. These efforts are expected to lead to prolonged survival and improved quality of life for NSCLC patients.
Source: https://pubmed.ncbi.nlm.nih.gov/42467409
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments